Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 44 entries
Sorted by: Best Match Show Resources per page
Endothelial Plasticity: Shifting Phenotypes through Force Feedback.

Stem cells international

Krenning G, Barauna VG, Krieger JE, Harmsen MC, Moonen JR.
PMID: 26904133
Stem Cells Int. 2016;2016:9762959. doi: 10.1155/2016/9762959. Epub 2016 Jan 24.

The endothelial lining of the vasculature is exposed to a large variety of biochemical and hemodynamic stimuli with different gradients throughout the vascular network. Adequate adaptation requires endothelial cells to be highly plastic, which is reflected by the remarkable...

Cite
Krenning G, Barauna VG, Krieger JE, et al. Endothelial Plasticity: Shifting Phenotypes through Force Feedback. Stem Cells Int. 2016;2016:9762959doi: 10.1155/2016/9762959.
Krenning, G., Barauna, V. G., Krieger, J. E., Harmsen, M. C., & Moonen, J. R. (2016). Endothelial Plasticity: Shifting Phenotypes through Force Feedback. Stem cells international, 20169762959. https://doi.org/10.1155/2016/9762959
Krenning, Guido, et al. "Endothelial Plasticity: Shifting Phenotypes through Force Feedback." Stem cells international vol. 2016 (2016): 9762959. doi: https://doi.org/10.1155/2016/9762959
Krenning G, Barauna VG, Krieger JE, Harmsen MC, Moonen JR. Endothelial Plasticity: Shifting Phenotypes through Force Feedback. Stem Cells Int. 2016;2016:9762959. doi: 10.1155/2016/9762959. Epub 2016 Jan 24. PMID: 26904133; PMCID: PMC4745942.
Copy Download .nbib Format: NLM
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [.

Pharmaceutics

Kanellopoulos P, Kaloudi A, Rouchota M, Loudos G, de Jong M, Krenning EP, Nock BA, Maina T.
PMID: 33256013
Pharmaceutics. 2020 Nov 26;12(12). doi: 10.3390/pharmaceutics12121145.

BACKGROUND: Peptide radioligands may serve as radionuclide carriers to tumor sites overexpressing their cognate receptor for diagnostic or therapeutic purposes. Treatment of mice with the neprilysin (NEP)-inhibitor phosphoramidon was previously shown to improve the metabolic stability and tumor uptake...

Cite
Kanellopoulos P, Kaloudi A, Rouchota M, et al. One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [. Pharmaceutics. 2020;12(12)doi: 10.3390/pharmaceutics12121145.
Kanellopoulos, P., Kaloudi, A., Rouchota, M., Loudos, G., de Jong, M., Krenning, E. P., Nock, B. A., & Maina, T. (2020). One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [. Pharmaceutics, 12(12), . https://doi.org/10.3390/pharmaceutics12121145
Kanellopoulos, Panagiotis, et al. "One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [." Pharmaceutics vol. 12,12 (2020). doi: https://doi.org/10.3390/pharmaceutics12121145
Kanellopoulos P, Kaloudi A, Rouchota M, Loudos G, de Jong M, Krenning EP, Nock BA, Maina T. One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [. Pharmaceutics. 2020 Nov 26;12(12). doi: 10.3390/pharmaceutics12121145. PMID: 33256013; PMCID: PMC7760338.
Copy Download .nbib Format: NLM
[No title available]

The Lancet. Oncology

Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP.
PMID: 34793718
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.

FUNDING: Advanced Accelerator Applications, a Novartis company.

Cite
Strosberg JR, Caplin ME, Kunz PL, et al. . Lancet Oncol. 2021;22(12):1752-1763doi: 10.1016/S1470-2045(21)00572-6.
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., Grande, E., Van Cutsem, E., Seregni, E., Duarte, H., Gericke, G., Bartalotta, A., Mariani, M. F., Demange, A., Mutevelic, S., Krenning, E. P. (2021). . The Lancet. Oncology, 22(12), 1752-1763. https://doi.org/10.1016/S1470-2045(21)00572-6
Strosberg, Jonathan R, et al. "." The Lancet. Oncology vol. 22,12 (2021): 1752-1763. doi: https://doi.org/10.1016/S1470-2045(21)00572-6
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. . Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. PMID: 34793718.
Copy Download .nbib Format: NLM
A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.

Purinergic signalling

Hasan D, Shono A, van Kalken CK, van der Spek PJ, Krenning EP, Kotani T.
PMID: 34757513
Purinergic Signal. 2021 Nov 10; doi: 10.1007/s11302-021-09814-6. Epub 2021 Nov 10.

Hyperinflammation plays an important role in severe and critical COVID-19. Using inconsistent criteria, many researchers define hyperinflammation as a form of very severe inflammation with cytokine storm. Therefore, COVID-19 patients are treated with anti-inflammatory drugs. These drugs appear to...

Cite
Hasan D, Shono A, van Kalken CK, et al. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling. Purinergic Signal. 2021;doi: 10.1007/s11302-021-09814-6.
Hasan, D., Shono, A., van Kalken, C. K., van der Spek, P. J., Krenning, E. P., & Kotani, T. (2021). A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling. Purinergic signalling, . https://doi.org/10.1007/s11302-021-09814-6
Hasan, Djo, et al. "A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling." Purinergic signalling vol. (2021). doi: https://doi.org/10.1007/s11302-021-09814-6
Hasan D, Shono A, van Kalken CK, van der Spek PJ, Krenning EP, Kotani T. A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling. Purinergic Signal. 2021 Nov 10; doi: 10.1007/s11302-021-09814-6. Epub 2021 Nov 10. PMID: 34757513; PMCID: PMC8578920.
Copy Download .nbib Format: NLM
Imaging inflammation in atherosclerotic plaques, targeting SST.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Meester EJ, Krenning BJ, de Blois E, de Jong M, van der Steen AFW, Bernsen MR, van der Heiden K.
PMID: 32026330
J Nucl Cardiol. 2021 Dec;28(6):2506-2513. doi: 10.1007/s12350-020-02046-y. Epub 2020 Feb 05.

BACKGROUND: Imaging Somatostatin Subtype Receptor 2 (SSTMETHODS AND RESULTS: Atherosclerotic ApoECONCLUSIONS: The results of this study indicate DOTA-JR11 as a promising ligand for visualization of atherosclerotic plaque inflammation.

Cite
Meester EJ, Krenning BJ, de Blois E, et al. Imaging inflammation in atherosclerotic plaques, targeting SST. J Nucl Cardiol. 2020;28(6):2506-2513doi: 10.1007/s12350-020-02046-y.
Meester, E. J., Krenning, B. J., de Blois, E., de Jong, M., van der Steen, A. F. W., Bernsen, M. R., & van der Heiden, K. (2021). Imaging inflammation in atherosclerotic plaques, targeting SST. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 28(6), 2506-2513. https://doi.org/10.1007/s12350-020-02046-y
Meester, Eric J, et al. "Imaging inflammation in atherosclerotic plaques, targeting SST." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 28,6 (2021): 2506-2513. doi: https://doi.org/10.1007/s12350-020-02046-y
Meester EJ, Krenning BJ, de Blois E, de Jong M, van der Steen AFW, Bernsen MR, van der Heiden K. Imaging inflammation in atherosclerotic plaques, targeting SST. J Nucl Cardiol. 2021 Dec;28(6):2506-2513. doi: 10.1007/s12350-020-02046-y. Epub 2020 Feb 05. PMID: 32026330; PMCID: PMC8709817.
Copy Download .nbib Format: NLM
Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification.

EJNMMI research

Meester EJ, de Blois E, Krenning BJ, van der Steen AFW, Norenberg JP, van Gaalen K, Bernsen MR, de Jong M, van der Heiden K.
PMID: 33730311
EJNMMI Res. 2021 Mar 17;11(1):27. doi: 10.1186/s13550-021-00772-z.

PURPOSE: Many radioligands have been developed for the visualization of atherosclerosis by targeting inflammation. However, interpretation of in vivo signals is often limited to plaque identification. We evaluated binding of some promising radioligands in an in vitro approach in...

Cite
Meester EJ, de Blois E, Krenning BJ, et al. Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification. EJNMMI Res. 2021;11(1):27doi: 10.1186/s13550-021-00772-z.
Meester, E. J., de Blois, E., Krenning, B. J., van der Steen, A. F. W., Norenberg, J. P., van Gaalen, K., Bernsen, M. R., de Jong, M., & van der Heiden, K. (2021). Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification. EJNMMI research, 11(1), 27. https://doi.org/10.1186/s13550-021-00772-z
Meester, Eric J, et al. "Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification." EJNMMI research vol. 11,1 (2021): 27. doi: https://doi.org/10.1186/s13550-021-00772-z
Meester EJ, de Blois E, Krenning BJ, van der Steen AFW, Norenberg JP, van Gaalen K, Bernsen MR, de Jong M, van der Heiden K. Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification. EJNMMI Res. 2021 Mar 17;11(1):27. doi: 10.1186/s13550-021-00772-z. PMID: 33730311; PMCID: PMC7969682.
Copy Download .nbib Format: NLM
A FOXO-dependent replication checkpoint restricts proliferation of damaged cells.

Cell reports

Hornsveld M, Feringa FM, Krenning L, van den Berg J, Smits LMM, Nguyen NBT, Rodríguez-Colman MJ, Dansen TB, Medema RH, Burgering BMT.
PMID: 33503422
Cell Rep. 2021 Jan 26;34(4):108675. doi: 10.1016/j.celrep.2020.108675.

DNA replication is challenged by numerous exogenous and endogenous factors that can interfere with the progression of replication forks. Substantial accumulation of single-stranded DNA during DNA replication activates the DNA replication stress checkpoint response that slows progression from S/G2...

Cite
Hornsveld M, Feringa FM, Krenning L, et al. A FOXO-dependent replication checkpoint restricts proliferation of damaged cells. Cell Rep. 2021;34(4):108675doi: 10.1016/j.celrep.2020.108675.
Hornsveld, M., Feringa, F. M., Krenning, L., van den Berg, J., Smits, L. M. M., Nguyen, N. B. T., Rodríguez-Colman, M. J., Dansen, T. B., Medema, R. H., & Burgering, B. M. T. (2021). A FOXO-dependent replication checkpoint restricts proliferation of damaged cells. Cell reports, 34(4), 108675. https://doi.org/10.1016/j.celrep.2020.108675
Hornsveld, Marten, et al. "A FOXO-dependent replication checkpoint restricts proliferation of damaged cells." Cell reports vol. 34,4 (2021): 108675. doi: https://doi.org/10.1016/j.celrep.2020.108675
Hornsveld M, Feringa FM, Krenning L, van den Berg J, Smits LMM, Nguyen NBT, Rodríguez-Colman MJ, Dansen TB, Medema RH, Burgering BMT. A FOXO-dependent replication checkpoint restricts proliferation of damaged cells. Cell Rep. 2021 Jan 26;34(4):108675. doi: 10.1016/j.celrep.2020.108675. PMID: 33503422.
Copy Download .nbib Format: NLM
miRetrieve-an R package and web application for miRNA text mining.

NAR genomics and bioinformatics

Friedrich J, Hammes HP, Krenning G.
PMID: 34988440
NAR Genom Bioinform. 2021 Dec 23;3(4):lqab117. doi: 10.1093/nargab/lqab117. eCollection 2021 Dec.

microRNAs (miRNAs) regulate gene expression and thereby influence biological processes in health and disease. As a consequence, miRNAs are intensely studied and literature on miRNAs has been constantly growing. While this growing body of literature reflects the interest in...

Cite
Friedrich J, Hammes HP, Krenning G. miRetrieve-an R package and web application for miRNA text mining. NAR Genom Bioinform. 2021;3(4):lqab117doi: 10.1093/nargab/lqab117.
Friedrich, J., Hammes, H. P., & Krenning, G. (2021). miRetrieve-an R package and web application for miRNA text mining. NAR genomics and bioinformatics, 3(4), lqab117. https://doi.org/10.1093/nargab/lqab117
Friedrich, Julian, et al. "miRetrieve-an R package and web application for miRNA text mining." NAR genomics and bioinformatics vol. 3,4 (2021): lqab117. doi: https://doi.org/10.1093/nargab/lqab117
Friedrich J, Hammes HP, Krenning G. miRetrieve-an R package and web application for miRNA text mining. NAR Genom Bioinform. 2021 Dec 23;3(4):lqab117. doi: 10.1093/nargab/lqab117. eCollection 2021 Dec. PMID: 34988440; PMCID: PMC8696973.
Copy Download .nbib Format: NLM
The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1.

Journal of personalized medicine

Fledderus J, Vanchin B, Rots MG, Krenning G.
PMID: 33562658
J Pers Med. 2021 Feb 05;11(2). doi: 10.3390/jpm11020103.

Endothelial cell inflammatory activation and dysfunction are key events in the pathophysiology of atherosclerosis, and are associated with an elevated risk of cardiovascular events. Yet, therapies specifically targeting the endothelium and atherosclerosis are lacking. Here, we review how endothelial...

Cite
Fledderus J, Vanchin B, Rots MG, et al. The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1. J Pers Med. 2021;11(2)doi: 10.3390/jpm11020103.
Fledderus, J., Vanchin, B., Rots, M. G., & Krenning, G. (2021). The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1. Journal of personalized medicine, 11(2), . https://doi.org/10.3390/jpm11020103
Fledderus, Jolien, et al. "The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1." Journal of personalized medicine vol. 11,2 (2021). doi: https://doi.org/10.3390/jpm11020103
Fledderus J, Vanchin B, Rots MG, Krenning G. The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1. J Pers Med. 2021 Feb 05;11(2). doi: 10.3390/jpm11020103. PMID: 33562658; PMCID: PMC7915331.
Copy Download .nbib Format: NLM
Imaging inflammation in atherosclerotic plaques, targeting SST.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Meester EJ, Krenning BJ, de Blois E, de Jong M, van der Steen AFW, Bernsen MR, van der Heiden K.
PMID: 32026330
J Nucl Cardiol. 2021 Dec;28(6):2506-2513. doi: 10.1007/s12350-020-02046-y. Epub 2020 Feb 05.

BACKGROUND: Imaging Somatostatin Subtype Receptor 2 (SSTMETHODS AND RESULTS: Atherosclerotic ApoECONCLUSIONS: The results of this study indicate DOTA-JR11 as a promising ligand for visualization of atherosclerotic plaque inflammation.

Cite
Meester EJ, Krenning BJ, de Blois E, et al. Imaging inflammation in atherosclerotic plaques, targeting SST. J Nucl Cardiol. 2020;28(6):2506-2513doi: 10.1007/s12350-020-02046-y.
Meester, E. J., Krenning, B. J., de Blois, E., de Jong, M., van der Steen, A. F. W., Bernsen, M. R., & van der Heiden, K. (2021). Imaging inflammation in atherosclerotic plaques, targeting SST. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 28(6), 2506-2513. https://doi.org/10.1007/s12350-020-02046-y
Meester, Eric J, et al. "Imaging inflammation in atherosclerotic plaques, targeting SST." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 28,6 (2021): 2506-2513. doi: https://doi.org/10.1007/s12350-020-02046-y
Meester EJ, Krenning BJ, de Blois E, de Jong M, van der Steen AFW, Bernsen MR, van der Heiden K. Imaging inflammation in atherosclerotic plaques, targeting SST. J Nucl Cardiol. 2021 Dec;28(6):2506-2513. doi: 10.1007/s12350-020-02046-y. Epub 2020 Feb 05. PMID: 32026330; PMCID: PMC8709817.
Copy Download .nbib Format: NLM
Imaging inflammation in atherosclerotic plaques, targeting SST.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Meester EJ, Krenning BJ, de Blois E, de Jong M, van der Steen AFW, Bernsen MR, van der Heiden K.
PMID: 32026330
J Nucl Cardiol. 2021 Dec;28(6):2506-2513. doi: 10.1007/s12350-020-02046-y. Epub 2020 Feb 05.

BACKGROUND: Imaging Somatostatin Subtype Receptor 2 (SSTMETHODS AND RESULTS: Atherosclerotic ApoECONCLUSIONS: The results of this study indicate DOTA-JR11 as a promising ligand for visualization of atherosclerotic plaque inflammation.

Cite
Meester EJ, Krenning BJ, de Blois E, et al. Imaging inflammation in atherosclerotic plaques, targeting SST. J Nucl Cardiol. 2020;28(6):2506-2513doi: 10.1007/s12350-020-02046-y.
Meester, E. J., Krenning, B. J., de Blois, E., de Jong, M., van der Steen, A. F. W., Bernsen, M. R., & van der Heiden, K. (2021). Imaging inflammation in atherosclerotic plaques, targeting SST. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 28(6), 2506-2513. https://doi.org/10.1007/s12350-020-02046-y
Meester, Eric J, et al. "Imaging inflammation in atherosclerotic plaques, targeting SST." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 28,6 (2021): 2506-2513. doi: https://doi.org/10.1007/s12350-020-02046-y
Meester EJ, Krenning BJ, de Blois E, de Jong M, van der Steen AFW, Bernsen MR, van der Heiden K. Imaging inflammation in atherosclerotic plaques, targeting SST. J Nucl Cardiol. 2021 Dec;28(6):2506-2513. doi: 10.1007/s12350-020-02046-y. Epub 2020 Feb 05. PMID: 32026330.
Copy Download .nbib Format: NLM
[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.

EJNMMI research

Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA.
PMID: 22682002
EJNMMI Res. 2012 Jun 09;2(1):25. doi: 10.1186/2191-219X-2-25.

BACKGROUND: In this study, we report on the synthesis, radiolabeling, and biological evaluation of two new somatostatin-14 (SS14) analogs, modified with the universal chelator DOTA. We were interested to investigate if and to what extent such radiotracer prototypes may...

Cite
Tatsi A, Maina T, Cescato R, et al. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Res. 2012;2(1):25doi: 10.1186/2191-219X-2-25.
Tatsi, A., Maina, T., Cescato, R., Waser, B., Krenning, E. P., de Jong, M., Cordopatis, P., Reubi, J. C., & Nock, B. A. (2012). [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI research, 2(1), 25. https://doi.org/10.1186/2191-219X-2-25
Tatsi, Aikaterini, et al. "[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study." EJNMMI research vol. 2,1 (2012): 25. doi: https://doi.org/10.1186/2191-219X-2-25
Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Res. 2012 Jun 09;2(1):25. doi: 10.1186/2191-219X-2-25. PMID: 22682002; PMCID: PMC3407795.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 44 entries